Your browser does not support javascript:   Search for gard hereSearch for news-and-events here.


Genetic and Rare Diseases Information Center (GARD)

Cutaneous T-cell lymphoma

Other Names for this Disease
  • CTCL
  • Primary cutaneous T-cell lymphoma
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.

News & Events

ORDR Co-Sponsored Conferences

  • 2016 Rare Disease Day at NIH, Monday, February 29, 2016
    Location: Building 10, Masur Auditorium, National Institutes of Health, Bethesda, MD
    Description: The 2016 Rare Disease Day at NIH will take place on February 29. The event, sponsored by NCATS and the NIH Clinical Center, aims to raise awareness about rare diseases, the patients they affect and the research collaborations that are addressing rare disease challenges. The day will feature tours, posters and exhibits, and presentations.

  • Advancing Symptom Clusters Research on Rare Cancers, Wednesday, June 17, 2015
    Location: NIH Neuroscience Building, Bethesda, MD
    Description: <p>It is intended that the in-depth, interdisciplinary dialogue of this expert working group will formulate an emerging consensus on a working definition of symptom clusters and, specific gaps and opportunities that provide a foundation for a transformative strategic blueprint to guide future symptom cluster research in rare cancers. In addition, it is anticipated that workshop proceedings will inform a funding opportunity announcement.</p>

  • Rare Tumors Initiative Symposium Strategies to Develop Therapies for Rare Tumors: Small Numbers, but Big Opportunities , Wednesday, June 17, 2015
    Location: NIH Natcher Conference Center, Bethesda, MD
    Description: The goals of this symposium are to increase communication and build networks between researchers working in rare tumors across NIH, and to get input from patient groups, industry, and the FDA on how to overcome the biggest hurdles in the development of therapies for rare tumors. The Rare Tumors Initiative at NCI, CCR will use this information to prioritize goals for the future and will prepare a white paper summary to help guide researchers worldwide.

  • Overcoming Barriers to International Clinical Trials for Rare Cancers , Friday, December 10, 2010
    Location: Bethesda, Maryland
    Description: The goals of this conference were to introduce key institutional players to the topic of international clinical trials in rare cancers and to establish an ongoing dialogue. Participants left the meeting with a set of specific priorities that need to be enacted to promote these trials. The meeting promoted consensus on the way that resources are prioritized to address rare cancers. Participants were asked to convey the content of the meeting to their constituencies and to follow up with pilot concepts.

  • Etiology of Rare Subtypes of Non-Hodgkin Lymphoma: An Interlymph Workshop, Monday, July 28, 2008 - Thursday, July 31, 2008
    Location: Sydney, Australia
    Description: The overarching goals of this conference were to identify specific risk factors that explain most of the occurrences of each of the rare NHL subtypes and to ascertain specific risk factors that may be linked with more than one subtype to better understand the determinants of lymphomagenesis. Scientific collaborations achieved from this meeting were aimed at enhancing interdisciplinary research in this understudied area of research.

  • Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL), Saturday, May 06, 2006 - Sunday, May 07, 2006
    Location: Holiday Inn Express, Philadelphia, PA
    Description: The cutaneous T-cell lymphomas represent a group of rare, non-Hodgkin’s lymphomas that are primarily localized to skin or have overt skin manifestations along with internal involvement. They are represented by mycosis fungoides, Sezary syndrome, CD30-positive skin lymphomas, and other variants. No treatment has been shown to be curative. Although most individuals have indolent disease, those with advanced disease obtain only partial, short-term benefit from chemotherapy and often die of disease or its most severe complication—infection and sepsis. There are several reasons to believe that cutaneous T-cell lymphomas may respond to or benefit from immunotherapy or immunoregulatory therapy. The goals of this conference were to educate the audience about new immuno-based therapies and strategies for CTCL and to bring together researchers and clinicians who treat CTCL to formulate strategies for clinical trials based on information disseminated in the meetings.

Other Names for this Disease
  • CTCL
  • Primary cutaneous T-cell lymphoma
See Disclaimer regarding information on this site. Some links on this page may take you to organizations outside of the National Institutes of Health.